The news of Leerink Partners initiating coverage on Edwards Lifesciences with a Market Perform rating and a price target of $75 is directly related to the company. This could influence investors' perception of the company and potentially impact its stock price. However, a Market Perform rating suggests that the stock is expected to perform in line with the market, indicating a neutral impact on the stock price in the short term.